Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Abstract: The present disclosure relates to a novel substituted pyrazole derivative having an effect of inhibiting serine/threonine kinase activity targeting receptor ALK5 of TGF-?, and a pharmaceutical composition including the compound of the present disclosure as an active ingredient may be useful in preventing and/or treating cancers, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, pulmonary diseases, cardiovascular diseases or metabolic diseases, or other diseases associated with a decrease in TGF family signaling activity.

Abstract: Provided is a novel imidazopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.

Abstract: Provided is a novel triazolopyridine derivative having irreversible tyrosine kinase inhibiting activities, and a pharmaceutical composition comprising the same which can be useful for prevention or treatment of inflammatory diseases, autoimmune diseases, proliferative diseases or hyperproliferative diseases, immunologically mediated diseases, cancers or tumors.

Abstract: A mobile communication terminal including a wireless communication unit configured to receive a call; a touch screen display configured to display indication information that the call is being received and to display a first soft touch item and a second soft touch item on the touch screen display when the call is being received; and a control unit configured to connect the call being received if the first soft touch item is selected, and to control the touch screen display to continue to display the indication information indicating that the call is being received if the second soft touch item is selected.

Abstract: An input device is provided. The input device includes a first input unit configured to provide at least two directional signals, a second input unit located in the first input unit, the second input unit including a housing and a rotatable member located therein, the second input unit being configured to provide at least two directional signals different from the at least two directional signals of the first input unit, and a circuitry supporting substrate configured to receive a signal that is input through the first input unit and the second input unit. A mobile communication device having the input device is also provided.

Abstract: A mobile communication terminal including a wireless communication unit configured to receive a call; a touch screen display configured to display indication information that the call is being received and to display a first soft touch item and a second soft touch item on the touch screen display when the call is being received; and a control unit configured to connect the call being received if the first soft touch item is selected, and to control the touch screen display to continue to display the indication information indicating that the call is being received if the second soft touch item is selected.

Abstract: A mobile communication terminal and method of connecting a call thereof are discussed. The mobile communication terminal according to an embodiment includes a wireless communication unit configured to receive a call, a display unit configured to display that the call is received and to output an image for selecting either a first item or a second item, if the call is received by the wireless communication unit, an input unit having a key for selecting either the first or second item, and a control unit configured to connect the received call if the first item is selected and to control the display unit to output an image for displaying that the call is received if the second is selected, when the upper body is closed against the lower body. Accordingly, a call is connected or a message is transceived even if the terminal is in the closed status.

Abstract: An input device is provided. The input device includes a first input unit configured to provide at least two directional signals, a second input unit located in the first input unit, the second input unit being configured to provide at least two directional signals different from the at least two directional signals of the first input unit, and a circuitry supporting substrate configured to receive a signal that is input through the first input unit and the second input unit. In addition, a mobile communication device having an input device is also provided.

Abstract: An input device is provided. The input device includes a first input unit configured to provide at least two directional signals, a second input unit located in the first input unit, the second input unit being configured to provide at least two directional signals different from the at least two directional signals of the first input unit, and a circuitry supporting substrate configured to receive a signal that is input through the first input unit and the second input unit. In addition, a mobile communication device having an input device is also provided.

Abstract: An input device is provided. The input device includes a first input unit configured to provide at least two directional signals, a second input unit located in the first input unit, the second input unit including a housing and a rotatable member located therein, the second input unit being configured to provide at least two directional signals different from the at least two directional signals of the first input unit, and a circuitry supporting substrate configured to receive a signal that is input through the first input unit and the second input unit. A mobile communication device having the input device is also provided.

Abstract: A mobile communication terminal and method of connecting a call thereof are discussed. The mobile communication terminal according to an embodiment includes a wireless communication unit configured to receive a call, a display unit configured to display that the call is received and to output an image for selecting either a first item or a second item, if the call is received by the wireless communication unit, an input unit having a key for selecting either the first or second item, and a control unit configured to connect the received call if the first item is selected and to control the display unit to output an image for displaying that the call is received if the second is selected, when the upper body is closed against the lower body. Accordingly, a call is connected or a message is transceived even if the terminal is in the closed status.

Abstract: This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc.

Abstract: A method for preparing a 1-androstene derivative which comprises reacting a 2-iodo-androstane derivative with an oxidizing agent while maintaining the pH of the reaction mixture at a specific range gives the 1-androstene derivative with high purity and yield.

Abstract: This invention relates to a method for selectively preparing the 3-oxo-4-aza-5¥á-androstane compound which is used as an intermediate of finasteride by heating 3-oxo-4-aza-5-androstene in a mixture of formic acid and an alkanediol in the presence of zinc.

Abstract: Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating cardiovascular diseases.

Abstract: Amlodipine camsylate of the present invention is a crystalline salt of amlodipine suitable for pharmaceutical formulation, which is prepared by using low toxic camphor sulfonic acid to meet required pharmaceutical properties for treating cadiovacular diseases.

Abstract: A binder composition for a photocatalytic coating is disclosed. The binder composition comprises 60-80 wt. % of a first monomer which is a non-fluoro containing monomer selected from the group consisting of acrylic monomers, methacrylic monomers, and mixtures thereof, having an aliphatic group and 20-40 wt. % of a second monomer which is at least one monomer selected from the group consisting of a fluoro containing monomer and a silicone monomer. The fluoro containing monomer is selected from the group consisting of styrene monomer, acrylic monomer and methacrylic monomer.

Abstract: Amlodipine is prepared in a high yield by subjecting a pyrrole derivative, methyl aminocrotonate and 2-chlorobenzaldehyde to a Hantzsch reaction, and converting the pyrrole residue of the resulting 1,4-dihydropyridine derivative to an amine group by the action of hydroxylamine hydrochloride.